Alma Medical has recently signed a collaboration agreement with the company Qubiotech, from Coruña (Spain), with the aim of incorporating its advanced and automatic neuroimaging analysis tools into the new digital health platform: Alma HEALTH PLATFORM.
With the integration of Qubiotech artificial intelligence algorithms, it will allow hundreds of radiologists, neurologists and nuclear imaging specialists to easily incorporate them into their clinical workflow, shifting from subjective assessments of neurodegenerative diseases (Parkinson’s, Alzheimer’s, epilepsy, multiple sclerosis…) to quantitative and reproducible assessments and eliminating interobserver differences.
Through the digital platform, the neurologist will be able to examine his studies and apply the algorithms to them for an automatic, fast and precise extraction of homogenized anomalous biomarkers. Thus he will save time and resources, but without sacrificing precision. It undoubtedly represents a support tool for the neurologist to confidently affirm his diagnosis, highlight anomalies and favor early detection.
The joint solution of the digital platform, together with the Qubiotech nuclear imaging analysis tool, turns out to be an excellent way to increase performance, reduce repetitions and improve the scalability of neurodegenerative disease detection.
About Qubiotech, AI-assisted analysis in neuroimaging
Qubiotech is an advanced neuroimaging processing company, based in Coruña (Spain), that provides accurate and effective tools for the quantification of biomarkers in neurodegenerative diseases.
It was born in the Neuroimaging Group of the University Hospital of Santiago de Compostela (Spain) with the aim of bringing innovation in molecular image analysis to real clinical practice and at a very low cost compared to the current alternatives.
Thus, it is a CE-certified solution that increases diagnostic security, favours early detection and accurate monitoring of pathologies. It facilitates collaboration between teams and increases their productivity.
Learn more about Qubiotech here.
